US firm Vical will carry out a phase 1 clinical trial of its Vaxfectin-formulated DNA vaccine for A/H1N1 pandemic swine flu influenza for the US Navy.
Free Buyers Guide
Leading Guide to Submarine and Submersible Suppliers for the Naval Industry
Thank you.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Your download email will arrive shortly. Please check your mail inbox to download the buyer's guide
You may also be interested in:
The funds will be provided by the navy through the Henry M Jackson Foundation for the Advancement of Military Medicine.
The investigational new drug application describing the trial design was approved by the US Food and Drug Administration in 2009.
According to the company, the navy funding builds on the success of our H5N1 vaccine, expand the safety and immunogenicity database for Vaxfectin-formulated vaccines in humans, and open the door to broader collaborations with the US Government.
Free Buyers Guide
Leading Guide to Submarine and Submersible Suppliers for the Naval Industry
Thank you.
Your download email will arrive shortly. Please check your mail inbox to download the buyer's guide
You may also be interested in:
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Naval Technology Excellence Awards - Nominations Closed
Nominations are now closed for the Naval Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action
Virtualitics has secured the Innovation and Business Expansion awards for its Integrated Readiness Optimization (IRO) suite. Discover how its explainable AI is transforming maintenance, sustainment and mission readiness, giving defence leaders faster, clearer, and more confident operational decisions.
